The apoA-I mimetic peptide 4F protects apolipoprotein A-I from oxidative damage

Aeschbach, 1976, Formation of dityrosine cross-links in proteins by oxidation of tyrosine residues, Biochim. Biophys. Acta, 439, 292, 10.1016/0005-2795(76)90064-7 Anantharamaiah, 1996, Chromatographic methods for quantitation of apolipoprotein A-I, Methods Enzymol., 263, 267, 10.1016/S0076-6879(96)63019-5 Anantharamaiah, 1988, Effect of oxidation on the properties of apolipoproteins A-I and A-II, J. Lipid Res., 29, 309, 10.1016/S0022-2275(20)38529-1 Barnaba, 2018, Lipid-exchange in nanodiscs discloses membrane boundaries of cytochrome-P450 reductase, Chem. Commun. (Camb.), 14, 6336, 10.1039/C8CC02003E Barnaba, 2018, Cytochrome-P450-induced ordering of microsomal membranes modulates affinity for drugs, Angew. Chem. Int. Ed. Engl., 57, 3391, 10.1002/anie.201713167 Bayburt, 2002, Self-assembly of discoidal phospholipid bilayer nanoparticles with membrane scaffold proteins, Nanoletters, 2, 853, 10.1021/nl025623k Chung, 1996, Single vertical spin density gradient ultracentrifugation, Methods Enzymol., 128, 181, 10.1016/0076-6879(86)28068-4 D’Silva, 2005, Mass spectrometric determination of the conformation of dimeric apolipoprotein A-I in discoidal high density lipoproteins, Biochemistry, 44, 8600, 10.1021/bi050421z Datta, 2001, Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide, J. Lipid Res., 42, 1096, 10.1016/S0022-2275(20)31599-6 Datta, 2004, Aromatic residue position on the nonpolar face of Class A amphipathic helical peptides determines biological activity, J. Biol. Chem., 279, 26509, 10.1074/jbc.M314276200 Denisov, 2004, Directed self-assembly of monodisperse phospholipid bilayer nanodiscs with controlled size, J. Am. Chem. Soc., 126, 3477, 10.1021/ja0393574 Gorden, 1977, High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study, Am. J. Med., 62, 707, 10.1016/0002-9343(77)90874-9 Handattu, 2009, Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer’s disease, Neurobiol. Dis., 34, 525, 10.1016/j.nbd.2009.03.007 Ibanez, 2012, Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type), Atherosclerosis, 220, 72, 10.1016/j.atherosclerosis.2011.10.006 Jin, 2010, Investigating the specific uptake of EGF-conjugated nanoparticles in lung cancer cells using fluorescence imaging, Cancer Nanotechnol., 1, 71, 10.1007/s12645-010-0009-x Kenneth, 2011, Lipoprotein-inspired nanoparticles for cancer theranostics, Acc. Chem. Res., 44, 1105, 10.1021/ar200017e Kingwell, 2014, HDL-targeted therapies: progress, failures and future, Nat. Rev. Drug Discov., 13, 445, 10.1038/nrd4279 Kritharides, 1998, Cholesterol metabolism and efflux in human THP-1 macrophages, Arterioscler. Thromb. Vasc. Biol., 18, 1589, 10.1161/01.ATV.18.10.1589 Navab, 2008, The effect of apolipoprotein mimetic peptides in inflammatory disorders other than atherosclerosis, Trends Cardiovasc. Med., 18, 61, 10.1016/j.tcm.2007.12.006 Navab, 2010, Structure and function of HDL mimetics, Arterioscler. Thromb. Vasc. Biol., 30, 164, 10.1161/ATVBAHA.109.187518 Navab, 2011, HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms, Nat. Rev. Cardiol., 8, 222, 10.1038/nrcardio.2010.222 Navab, 2011, Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally, J. Lipid Res., 52, 1200, 10.1194/jlr.M013144 Nissen, 2003, Effect of recombinant apoA-I milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial, JAMA, 290, 2292, 10.1001/jama.290.17.2292 Prade, 2018, A minimal functional complex of cytochrome P450 and FBD of cytochrome P450 reductase in nanodiscs, Angew. Chem. Int. Ed. Engl., 57, 8458, 10.1002/anie.201802210 Reddy, 2013, Searching for a successful HDL-based treatment strategy, Biochim. Biophys. Acta, 1841, 162, 10.1016/j.bbalip.2013.10.012 Rye, 2009, The metabolism and anti-atherogenic properties of HDL, J. Lipid Res., 50, S195, 10.1194/jlr.R800034-JLR200 Sahoo, 2018, Nanodisc-forming scaffold protein promoted retardation of amyloid-beta aggregation, J. Mol. Biol., 430, 4230, 10.1016/j.jmb.2018.08.018 Shah, 2001, High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice. Potential implications for acute plaque stabilization, Circulation, 103, 3047, 10.1161/hc2501.092494 Shaw, 2008, Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque, Circ. Res., 103, 1084, 10.1161/CIRCRESAHA.108.182063 Skajaa, 2010, Quantum dot and Cy5.5 labeled nanoparticles to investigate lipoprotein biointeractions via F€orster resonance energy transfer, ACS Nano, 10, 5131 Sorci-Thomas, 1997, Alteration in Apolipoprotein A-I 22-mer repeat order results in a decrease in lecithin:cholesterol acyltransferase reactivity, J. Biol. Chem., 272, 7278, 10.1074/jbc.272.11.7278 Tardif, 2007, Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial, JAMA, 297, 1675, 10.1001/jama.297.15.jpc70004 Tricerri, 2002, Interaction of apolipoprotein A-I in three different conformations with palmitoyl oleoyl phophatidylcholine vesicles, J. Lipid Res., 43, 187, 10.1016/S0022-2275(20)30160-7 Van Lenten, 1995, Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response, Clin. Invest., 96, 2758, 10.1172/JCI118345 Van Lenten, 2008, Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I, J. Lipid Res., 49, 2302, 10.1194/jlr.M800075-JLR200 White, 2012, Preservation of biological function despite oxidative modification of the apolipoprotein A-I mimetic peptide 4F, J. Lipid Res., 53, 1576, 10.1194/jlr.M026278 White, 2014, Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics, J. Lipid Res., 55, 2007, 10.1194/jlr.R051367 Zhang, 2009, Biomimetic nanocarrier for direct cytosolic drug delivery, Angew. Chem. Int. Ed., 48, 9171, 10.1002/anie.200903112